Clinical Pharmacokinetics of Amfetamine and Related Substances

@article{Torre2004ClinicalPO,
  title={Clinical Pharmacokinetics of Amfetamine and Related Substances},
  author={Rafael de la Torre and Mag{\'i} Farr{\'e} and M. Dolores S{\'a}nchez Navarro and Roberta Pacifici and Piergiorgio Zuccaro and Simona Pichini},
  journal={Clinical Pharmacokinetics},
  year={2004},
  volume={43},
  pages={157-185}
}
Consumption of amfetamine-type stimulants, including classical amfetamines and ‘designer drugs’, has been recognised as one of the most significant trends in drug abuse at the end of the past century and at the beginning of the current one. The first cause is the increasing consumption amongst youth of methylenedioxy- and methoxy-substituted amfetamines, of which the pharmacology in humans is currently under investigation. Secondly, the abuse of more classical amfetamines, such as amfetamine… Expand
A mechanistic insight into 3,4-methylenedioxymethamphetamine (“ecstasy”)-mediated hepatotoxicity
TLDR
An overview of the literature and the latest findings with respect to the mechanism of MDMA-mediated liver toxicity is described, showing a critical starting point appears to be the hepatic metabolism of MDMA by phase I and II enzymes, leading to reactive metabolites. Expand
Fenproporex and Amphetamine Pharmacokinetics in Oral Fluid After Controlled Oral Administration of Fenproporex
TLDR
Oral administration of FEN resulted in significant amounts of Fenproporex hydrochloride and AMP in oral fluid, showing that oral fluid could be a biological matrix suitable for pharmacokinetic studies for both analytes. Expand
Voltammetric detection of 3,4-methylenedioxymethamphetamine (mdma) in saliva in low cost systems
TLDR
It is demonstrated that it is possible to identify MDMA in oral fluid using the carbon paste electrode, as working and auxiliary electrodes, and the screen printed carbon electrode (SPCE) with cyclic and square wave voltammetry, demonstrating that it can be applied to identify the recent use of the drug, as well as the rapid tests already commercialized. Expand
Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject.
TLDR
The results suggest that measurement of MPH in oral fluid can be used as a potential alternative to drug monitoring in plasma and MPH measurement in sweat patches can be use for noninvasive monitoring of MPH consumption and misuse in situations where detection of recent abuse is of interest. Expand
Determination of Amphetamine and Methylphenidate in Exhaled Breath of Patients Undergoing Attention-Deficit/Hyperactivity Disorder Treatment
TLDR
It is confirmed that amphetamine is present in exhaled breath after intake and for the first time the presence of methylphenidate and ritalinic acid after its intake gives further support to the potential use of exhale breath for detecting drug intake. Expand
Toxicity of amphetamines: an update
TLDR
The long-studied classical amphetamines—amphetamine itself, as well as methamphetamine and MDMA provide plenty of data that may be useful to predict toxicological outcome to improvident abusers and are for that reason the main focus of this review. Expand
A mechanistic insight into MDMA-mediated hepatotoxicity
methylenedioxymethamphetamine (MDMA, Ecstasy) is a popular drug of abuse among young people that can induce adverse effects. However, these effects lack a specific pattern, as consumption quantitiesExpand
Usefulness of Sweat Testing for the Detection of Methylphenidate After Fast- and Extended-Release Drug Administration: A Pilot Study
TLDR
The pharmacokinetics of methylphenidate (MPH), a prescription amphetamine derivative used in the treatment of attention-deficit hyperactivity disorder, and its principal metabolite, ritalinic acid, in oral fluid and plasma after a single drug administration are described. Expand
Non-invasive monitoring of pharmacokinetics and pharmacodynamics for pharmacological drug profiling in children and adolescents
TLDR
Two clinical trials were designed to evaluate age-appropriate formulations of sedative drugs that have the potential for use in children and the feasibility of using saliva as an alternative to plasma in two studies on psychostimulants. Expand
The role of sertonin and vesicular monoamine transporters in the adverse responses to methylenedioxymethamphetamine
3,4-(±)-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely abused amphetamine derivative with potent stimulant properties. The neuropharmacological effects of MDMA are biphasic in nature. MDMAExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 192 REFERENCES
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.
TLDR
The lack of linearity of MDMA pharmacokinetics (in a window of doses compatible with its recreational use) is a more general phenomenon as it concerns the whole population independent of their CYP2D6 genotype. Expand
Clinical Pharmacokinetics of Non-Opiate Abused Drugs
TLDR
The clinical significance of kinetic characteristics with respect to abuse is discussed where possible and the pharmacokinetic properties that presumably contribute to self-administration and drug abuse include rapid delivery of the drug into the central nervous system and high free drug clearance. Expand
Analysis of 4-methylthioamphetamine in clinical specimens
  • S. Elliott
  • Chemistry, Medicine
  • Annals of clinical biochemistry
  • 2001
TLDR
Analysis of various plasma and urine specimens in three clinical cases implicating 'Ecstasy' ingestion revealed the presence of 4-MTA, and this paper presents the first reported non-fatal instances of 4.MTA intoxication in the UK. Expand
Pharmacokinetics and Clinical Effectiveness of Methylphenidate
TLDR
It is difficult to predict which children will have a favourable response to methylphenidate, and therefore dosage must be titrated for optimal effect and avoidance of toxicity in each child, and further studies of the relationship between the pharmacokinetic and pharmacodynamic properties are required to allow the development of optimal dosage regimens. Expand
CYP2D6 deficiency, a factor in ecstasy related deaths?
TLDR
Compared the prevalence of the CYP2D6 PM genotype with that in the general population, using a PCR assay to analyse post mortem samples from individuals believed to have died from ecstasy related toxicity, it is found that those with levels of enzyme in the normal range, known as poor metabolizers [PM] are not predicted to be PM. Expand
Metabolic production of amphetamine following multidose administration of clobenzorex.
TLDR
This analysis revealed that the metabolite, (amphetamine) is present in much higher concentrations than the parent compound, clobenzorex, yet even at peak amphetamine concentrations, the parent was not always detected (limit of detection 1 ng/mL). Expand
Detection of amphetamine following administration of fenproporex.
TLDR
Analysis of the metabolically produced amphetamine showed the presence of both enantiomers, which can be helpful in the differentiation of some illicit amphetamine use from the use of this precursor drug. Expand
3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans
TLDR
This review examines the relevant human and animal literature to delineate the possible risks MDMA, MDA and MDE engender with oral consumption in humans and discusses toxicity, psychopathology, neurotoxicity, abuse potential and the potential for drug-drug interactions associated with acute and chronic use. Expand
Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA).
TLDR
Three recent fatalities that occurred in the midwestern United States in which each of the decedents believed that they were ingesting MDMA were reported, and PMA is not a contaminant of MDMA, and no MDMA was found in any of these cases. Expand
The metabolism of (−)-ephedrine in man
TLDR
No phenolic metabolites could be detected, and thus it would appear that these compounds cannot be implicated in the acquisition of tolerance to ephedrine which can occur on repeated dosage. Expand
...
1
2
3
4
5
...